🔎 Trials Near Me

Beranda › Limfoma Burkitt › Distrik Columbia › Washington

Uji klinis Limfoma Burkitt di Washington, DC

9 studi untuk Limfoma Burkitt mencari peserta di lokasi sekitar Washington (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Menerima pesertaFase 2
  • MedStar Georgetown University Hospital, Washington D.C.
  • Children's National Medical Center, Washington D.C.
  • Walter Reed National Military Medical Center, Bethesda · 7 mi jauhnya
366 Days – 46 Years · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06124157

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Menerima pesertaFase 1/2
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauhnya
Usia 3 hingga 39 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT05442515

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Menerima pesertaFase 2
  • MedStar Georgetown University Hospital, Washington D.C.
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT03739814

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Menerima pesertaFase 1/2
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauhnya
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT03223610

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Menerima pesertaFase 3
  • American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT07648264

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Menerima pesertaFase 2
  • Children's National Medical Center, Washington D.C.
Usia 1 hingga 30 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Menerima pesertaFase 3
  • Children's National Medical Center, Washington D.C.
  • Walter Reed National Military Medical Center, Bethesda · 7 mi jauhnya
365 Days – 25 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT03959085

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Menerima pesertaFase 1
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauhnya
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT05389423

Uji klinis Limfoma Burkitt di kota lain

Studi lain di Washington

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.